Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance
Mei Hua Gao, … , Da Young Oh, H. Kirk Hammond
Mei Hua Gao, … , Da Young Oh, H. Kirk Hammond
Published September 22, 2016
Citation Information: JCI Insight. 2016;1(15):e88322. https://doi.org/10.1172/jci.insight.88322.
View: Text | PDF
Research Article Therapeutics

One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance

  • Text
  • PDF
Abstract

Using mice rendered insulin resistant with high fat diets (HFD), we examined blood glucose levels and insulin resistance after i.v. delivery of an adeno-associated virus type 8 encoding murine urocortin 2 (AAV8.UCn2). A single i.v. injection of AAV8.UCn2-normalized blood glucose and glucose disposal within weeks, an effect that lasted for months. Hyperinsulinemic-euglycemic clamps showed reduced plasma insulin, increased glucose disposal rates, and increased insulin sensitivity following UCn2 gene transfer. Mice with corticotropin-releasing hormone type 2-receptor deletion that were rendered insulin resistant by HFD showed no improvement in glucose disposal after UCn2 gene transfer, indicating that the effect requires UCn2’s cognate receptor. We also demonstrated increased glucose disposal after UCn2 gene transfer in db/db mice, a second model of insulin resistance. UCn2 gene transfer reduced fatty infiltration of the liver in both models of insulin resistance. UCn2 increases Glut4 translocation to the plasma membrane in skeletal myotubes in a manner quantitatively similar to insulin, indicating a mechanism through which UCn2 operates to increase insulin sensitivity. UCn2 gene transfer, in a dose-dependent manner, is insulin sensitizing and effective for months after a single injection. These findings suggest a potential long-term therapy for clinical type-2 diabetes.

Authors

Mei Hua Gao, Dimosthenis Giamouridis, N. Chin Lai, Evelyn Walenta, Vivian Almeida Paschoal, Young Chul Kim, Atsushi Miyanohara, Tracy Guo, Min Liao, Li Liu, Zhen Tan, Theodore P. Ciaraldi, Simon Schenk, Aditi Bhargava, Da Young Oh, H. Kirk Hammond

×

Figure 4

UCn2 gene transfer in HFD-induced insulin resistance in CRHR2-deleted mice.

Options: View larger image (or click on image) Download as PowerPoint
UCn2 gene transfer in HFD-induced insulin resistance in CRHR2-deleted mi...
(A) Plasma UCn2 in CRHR2-deleted mice. First, we confirmed that i.v. AAV8.UCn2 (5 × 1011 gc, i.v.) was associated with increased plasma UCn2 levels in CRHR2-deleted (KO) HFD-fed mice. Plasma UCn2 peptide was measured in pooled plasma (4 animals per group). High plasma levels of UCn2 were detected, in amounts similar to what we found in normal mice (5). (B) Glucose tolerance test 17 weeks after HFD, UCn2 gene transfer at 8 weeks. Fasted CRHR2-deleted mice received glucose (2 mg/g, i.p.), and glucose was measured sequentially for 120 min. There was no group difference in blood glucose levels (P = 0.21, AUC), indicating that UCn2’s cognate receptor, CRHR2, is required for UCn2 to increase glucose disposal rate. Contrast these data to those shown in Figure 2A, where a pronounced glucose lowering effect of UCn2 gene transfer is observed.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts